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Summary 
Over a century ago, hyperplasia and hypertrophy of astrocytes 
was noted as a histopathological hallmark of multiple sclerosis 
and was hypothesized to play an important role in the 
development and course of this disease. However until today, the 
factual contribution of astrocytes to multiple sclerosis is elusive. 
Astrocytes may play an active role during degeneration and 
demyelination by controlling local inflammation in the CNS, 
provoking damage of oligodendrocytes and axons, and glial 
scarring but might also be beneficial by creating a permissive 
environment for remyelination and oligodendrocyte precursor 
migration, proliferation, and differentiation. Recent findings from 
our lab suggest that brain lipid binding protein (FABP7) is 
implicated in the course of multiple sclerosis and the regulation 
of astrocyte function. The relevance of our findings and data 
from other groups are highlighted and discussed in this paper in 
the context of myelin repair. 
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Astroglia: General remarks 
 
 It is well-known that glial cells are more than 
‘glue’-material between neurons, a “function” originally 
suggested by Rudolf Virchow in the mid 19th century. 
Astrocytes represent a subpopulation of macroglia in the 
peripheral and central nervous system (CNS). Since the 
late nineteenth century, astrocytes have been divided 
based on their morphology into two main subtypes: 
protoplasmic (lat. astrocytus protoplasmaticus) and 
fibrous astrocytes (lat. astrocytus fibrosus). Protoplasmic 
astrocytes are present throughout the gray matter and 
exhibit morphological characteristics such as several stem 
branches that, in turn, give rise to finely branching 
processes in a uniform globoid distribution. In contrast 
fibrous astrocytes are found throughout the white matter 
and display many long fibre-like processes (from Ramon 
Y, Cajal S; 1909: Histologie du systeme nerveux de 
l’homme et des vertebres). Astroglia function exceeds by 
far a solely supportive role in neural tissue. These cells 
are dynamic, capable of communicating with neurons and 
other glial cells. Their processes extend to neuronal 
synapses, nodes of Ranvier, and to the blood-brain barrier 
(BBB), and they are interconnected via gap junctions to 
each other as well as to oligodendrocytes (Venance et al. 
1995, Rash et al. 2001). Astroglia are essential for the 
physical structuring of the brain, metabolism, and 
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synaptic functioning in addition to their role in 
responding to pathological insults. Such insults provoke a 
graded cellular activation referred to as reactive gliosis 
(Faulkner et al. 2004, Pekny and Nilsson 2005). 
 There is a growing body of evidence suggesting 
that the loss of normal astrocyte function or acquisition of 
non-physiological properties contribute to, or are even 
considered as, the primary cause of the genesis of human 
brain diseases. Alexander disease (AD) represents one of 
those disorders linking astrocyte dysfunction with disease 
pathogenesis (Li et al. 2002, Quinlan et al. 2007, 
Sawaishi 2009). AD is a progressive, usually fatal 
neurological disorder, and can be divided into an 
infantile, juvenile, and adult form. Although all three 
forms of AD can differ markedly in their clinical, para-
clinical, and pathological presentation, they are united by 
the abundance of so-called “Rosenthal fibers” which are 
protein aggregates within astrocytes composed inter alia 
of glial fibrillary acidic protein (GFAP), αB-crystallin, 
and heat shock protein 27 (Ma et al. 2007). AD is a rare 
genetic disorder caused by mutations in the gene for 
GFAP – a type III intermediate filament protein 
transcribed from a 10 kb region located on chromosome 
17 in humans and 11 in the mouse. Mice lacking this 
intermediate filament protein still display normal 
development and reproduction (Pekny et al. 1995). In 
contrast, astrocytes of transgenic mice with an over-
expression of the human GFAP gene, reveal inclusions 
resembling Rosenthal fibres (Messing et al. 1998). 
Following these interesting findings, Brenner and 
colleagues showed that heterozygous miss-sense 
mutations of GFAP are associated with AD, establishing 
this rare disorder as the first example of a primary genetic 
disorder of astrocytes (Brenner et al. 2001).  
 Another example of a dysfunction of astrocytes 
associated with brain pathology is neuromyelitis optica. 
Neuromyelitis optica (NMO or Devic's disease) is a 
severe autoimmune inflammatory and demyelinating 
disease of the CNS which predominantly affects the 
spinal cord and the optic nerve (Jarius and Wildemann 
2010, Saikali et al. 2009). Although previously referred 
to as a subtype of multiple sclerosis (MS), the recent 
description of NMO-IgG, a highly disease-specific 
autoantibody found in NMO but absent in the classical 
form of MS, convincingly demonstrated that NMO is a 
specific disease and not just a subtype of MS. The target 
antigen of NMO-IgG was identified as aquaporin-4 
(AQP4), the main water channel protein in the CNS, 
expressed on astrocyte end-feet at the BBB and brain-
cerebrospinal fluid-barrier (Lennon et al. 2004). AQP4 
plays a crucial role in the regulation of water fluxes from 
the extra- to the intracellular compartment in the CNS. 
A series of clinical and pathologic observations strongly 
suggest that auto-antibodies directed against astrocytic 
AQP4 play a central role in the physiopathology of NMO 
(Jarius et al. 2008). 
 
Astroglia: Relevance for multiple sclerosis 
 
 MS, also known as disseminated sclerosis or 
encephalomyelitis disseminata, is a chronic, 
inflammatory, and demyelinating disease that affects the 
CNS. It is the most common neurological disorder in 
young adults in the Western hemisphere with a female 
prevalence. MS appears in several courses with new 
symptoms either in discrete episodes (relapsing-remitting 
form) or slowly accumulating over time (progressive 
form). Most patients are diagnosed with relapsing-
remitting MS but enter at later stages the secondary-
progressive stage. Between such episodes, symptoms 
may disappear completely. However, neurological 
problems often persist, especially as disease progresses. 
Besides lymphocytes and other leukocytes, astroglia and 
microglia contribute to the cellular composition of 
inflammation in MS lesions (van der Valk and De Groot 
2000). As stated above, astroglia are pivotal regulators of 
intra-cerebral inflammatory processes and are required to 
protect nerve cells from pathological threats. Activation, 
proliferation, and morphological alterations of astrocytes 
are histopathological hallmarks of human MS and its 
related animals models such as experimental autoimmune 
encephalomyelitis (EAE) and toxin- and virus-induced 
demyelination (Gold et al. 2006, Lassmann 2008, Kipp et 
al. 2009).  
 Following the trend-setting documentation of 
gross anatomical changes in the CNS of MS patients by 
R. Carswell (1883), J. Cruveilhier (1829) and G.T. 
Valentiner (1856), the first detailed description of 
microscopic pathology of MS is ascribed to J.M. Charcot. 
In 1868, he published the manuscript “Histologie de la 
sclerose en plaque” (Gaz Hopital, Paris, 41:554-566) 
summarizing previous reports and adding his own clinical 
and pathological observations (Lassmann 2005). The 
terms “disseminated sclerosis” or “encephalomyelitis 
disseminata” describe the main pathological findings in 
the MS brain which are disseminated sclerotic plaques. 
The sclerotic aspect is due to a tissue scar formed by 
astrocytes. In the most common (Charcot) type of MS, 
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plaques of demyelination are interspersed with and 
surrounded by reactive astrocytes. In addition, 
widespread focal reactive astrogliosis of varying intensity 
throughout white and gray matter is characteristic of the 
disease. Astrocytes during MS may also demonstrate the 
phenomenon of ‘emperipolesis’, i.e., an astrocyte 
apparently engulfing one or more other cells such as 
oligodendroglia (Ghatak 1992) and lymphocytes (Furer et 
al. 1993). The role of astrocytes during MS and related 
disorders is under intense investigation. Astrocytes play 
an active role during degeneration and demyelination by 
promoting inflammation, damage of oligodendrocytes 
and axons, and glial scarring but might also be beneficial 
by creating a permissive environment for remyelination 
and oligodendrocyte precursor migration, proliferation, 
and differentiation. Astrocytes secrete a multitude of 
harmful cytokines such as tumor necrosis factor alpha 
(TNF-α) or interleukin 1β (IL-1β) as well as pro-
inflammatory prostaglandins (Karakaya et al. 2007, 
Johann et al. 2008, Kipp et al. 2008). This makes it likely 
that astrocytes are implicated in oligodendrocyte damage 
and, in consequence, in promoting demyelination. 
Furthermore, it has been shown that the 
glycosaminoglycan hyaluronan, synthesized by activated 
astrocytes accumulates in chronically demyelinated 
human MS lesions and inhibits oligodendrocyte 
progenitor (OPC) differentiation and consequently 
remyelination (Back et al. 2005). On the other hand, 
astrocytes might contribute to regeneration and 
remyelination by secreting important growth factors, i.e., 
platelet-derived growth factor (PDGF), insulin-like 
growth factor 1, and basic fibroblast growth factor. All of 
these factors are known to promote remyelination and 
prevent oligodendrocyte apoptosis. Of relevance is a 
recently published review article which focuses on 
astrocytes as producers of secreted factors that can either 
promote or impede myelination within the CNS and how 
these cells are currently thought to be involved in the 
myelin pathology of MS (Moore et al. 2011).  
 We stress at this point that the secretion of pro-
inflammatory molecules such as TNF-α or IL-1β from 
astrocytes does not necessarily have a negative impact on 
MS disease progression. The importance of inflammation 
for endogenous remyelination is well-documented (Patani 
et al. 2007). The cytokines TNF-α and IL-1β promote 
proliferation of oligodendrocyte progenitors and 
remyelination (Arnett et al. 2001, Mason et al. 2001). 
Major histocompatibility complex-II (MHC-II)-null mice 
display delayed remyelination and regeneration of 
oligodendrocytes compared to their wild type littermates 
after cuprizone or Theiler's virus-induced demyelination 
(Njenga et al. 1999, Arnett et al. 2003). Furthermore, the 
activation of inflammatory response by a combination of 
growth factors leads to myelin repair (Biancotti et al. 
2008) clearly demonstrating a beneficial role for 
inflammation in the CNS. Other factors related to 
inflammation, such as interferon-γ (Lin et al. 2006, Mana 
et al. 2006), however, might be more detrimental for 
remyelination. Understanding of the dual role of 
inflammatory cytokines/factors to enable control and 
manipulation of these responses thus represents a major 
goal for the development of new therapies.  
 
Astrocytes adopt different functions during 
their lifespan and pathological challenges 
 
 One intriguing issue is whether activated 
astrocytes respond in a uniform manner or whether 
differences in astrocytes response upon brain injury exist. 
In recent studies, we performed experiments using 
primary cultured astrocytes from different brain regions 
for a better understanding of the function of astrocytes 
during brain pathology. Our results clearly demonstrate 
that astroglia actively respond to diverse pathological 
compounds by a selective expression pattern of growth 
factors. Astroglia cultures were exposed to different 
neurotoxic compounds at non-toxic concentrations, and 
growth factor expression was analyzed by PCR, oligo-
microarray, and ELISA. Expression of IGF-1 was 
selectively down-regulated by exposure to LPS and  
TNF-α, expression of bone morphogenetic protein 6 was 
decreased by all stimuli. In contrast, LPS, TNF-α and 
glutamate increased leukaemia inhibitory factor 
expression. Fibroblast growth factor-2 expression was 
up-regulated by LPS and TNF-α, but down-regulated by 
hydrogen peroxide. Besides hydrogen peroxide, all other 
stimuli promoted VEGF-A expression. These findings 
make astrocytes likely candidates to participate in 
disease-specific characteristics of neuronal and 
oligodendroglial support or damage (Braun et al. 2009).  
 In another study, we investigated the potency of 
LPS to differentially stimulate astrocytes from the cortex 
and midbrain. Astrocytes from both brain areas already 
differed in their capacity and profile of cytokine 
expression under basal un-stimulated conditions. For 
example, GM-CSF, IL-13, and RANTES mRNA 
transcripts were present at significantly higher levels in 
the cortex compared to the midbrain, whereas IL-2,  
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M-CSF, P-Selectin, and MIP-3α were conversely reduced 
in cultured cortical astroglia. The exposure to LPS not 
only resulted in a similar induction of some proteins in 
both brain regions but also disclosed differential 
regulation of others. The expression of G-CSF, IL-2, and 
P-selectin was only stimulated in cortical cells by LPS. In 
contrast, IL-1α, IL-5, IL-6, MCP-1, MCSF, MIP-3α, 
RANTES, and TNF-α were all significantly increased 
after LPS challenge in midbrain and cortical astrocytes 
although to a different extent.  
 These data demonstrate that astrocytes reveal a 
region-specific basal profile of cytokine expression and a 
selective area-specific regulation of cytokines upon LPS-
induced inflammation (Kipp et al. 2008). Our results 
highlight that the impact of astrocytes on MS pathology 
might differ between different brain regions. Since it is 
well-known that the composition of the inflammatory 
infiltrate changes during disease course (inflammation is 
less prominent in chronic disease stages), the function of 
astrocytes likely varies as disease progresses.  
 
Cuprizone-induced de- and remyelination as 
a model to study failure of remyelination 
 
 It is apparent that astrocytes possess a dual role 
in MS disease progression. We assume that the activation 
of astrocytes is beneficial during the initial disease stages, 
however, after sustained tissue injury, a switch from a 
beneficial towards a deleterious astroglia function occurs. 
In a recent study, we aimed to identify the regeneration-
inducing population of astrocytes. This identification was 
performed using the toxic de-/remyelination cuprizone 
model. Cuprizone ingestion in mice induces a highly 
reproducible demyelination of distinct brain regions, such 
as the corpus callosum (CC) (Clarner et al. 2011, Groebe 
et al. 2009, Kipp et al. 2009, Norkute et al. 2009, Pott et 
al. 2009). After 5-6 weeks of cuprizone treatment, the CC 
is almost completely demyelinated, a process called 
"acute demyelination". This process is followed by 
spontaneous remyelination when mice are fed normal 
chow. In contrast, remyelination is highly impaired when 
cuprizone administration is prolonged (13 weeks or 
longer), a process called "chronic demyelination". By 
using this model, repair processes can be clearly defined 
i.e. reappearance of myelin in previously demyelinated 
areas. In other disease models, regeneration is more 
difficult to pin-point. It has been postulated that 
remyelination completely fails after a chronically 
cuprizone-induced demyelination (13 weeks) event (Vana 
et al. 2007, Harsan et al. 2008), whereas other reports 
suggest that remyelination does not completely fail but is 
delayed (Lindner et al. 2009). We reassessed the 
remyelination capacity after acute and chronic cuprizone-
induced demyelination. In these studies male mice were 
fed cuprizone (0.2 %) for 5 weeks to induce acute 
demyelination, or 13 weeks to induce chronic 
demyelination. Remyelination was analyzed after a  
4-week period. Under these conditions, the CC is 
severely demyelinated after 5 and 13 weeks of cuprizone 
treatment as demonstrated by anti-PLP 
immunohistochemsitry (Figs 1b/c). The myelin status of 
the CC significantly improves after acute demyelination 
during a 4-week follow-up period shown by a recovery of 
PLP immunoreactivity (Figs 1d/e). In contrast, 
endogenous remyelination almost completely fails after 
chronic cuprizone exposure. Nevertheless, APC-positive 
oligodendrocytes are still present within the acutely and 
chronically demyelinated lesion (inserts in Figs 1d/e). 
Our findings indicate that in the chronically demyelinated 
CC, remyelination is highly impaired despite 
repopulation with pre-mature oligodendrocytes, similar to 
what is found in chronic lesions of MS patients (Chang et 
al. 2002). To identify genes related to endogenous 
remyelination which are induced in the CC, Affymetrix 
GeneChip® arrays were applied. Brain lipid binding 
protein (BLBP) also termed fatty acid binding protein 7 
(FABP7) was identified as being highly expressed in the 
remyelinating CC. This class of fatty acid-binding 
proteins are cytoplasmic 14-15 kDa proteins involved in 
fatty acid uptake, transport and metabolism. Nine FABP 
types can be discerned with a tissue specific distribution 
pattern (Veerkamp and Zimmerman 2001). Brain FABP, 
also called FABP7 or BLBP, is widely used as a radial 
glia cell marker (Bibel et al. 2004, Barry and McDermott 
2005, Patrikios et al. 2006, Sibbe et al. 2009). Radial glia 
plays an essential role in the laminar organization of 
neurons in the cerebral cortex (Rakic 1971, 1972). Due to 
its abundant expression in the acutely demyelinated CC, 
we assume that expression of FABP7 in activated 
astrocytes might play a role during remyelination.  
 
Expression of FABP7 in the normal and 
injured brains 
 
 Schmid et al. (2006) used transgenic mice under 
the control of the FABP7 promoter to study the cellular 
distribution and morphology of FABP7-expressing cells. 
Their results suggest that during early postnatal days, 
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radial glia transform into GFAP+ astrocytes and the 
FABP7 promoter remains active in astrocytes. Consistent 
with this, they observed FABP7 expression in GFAP+ 
astrocytes of the adult cerebral cortex and hippocampus. 
FABP7/GFAP double-positive cells were primarily found 
in the outer layers of the cortex extending to the pial 
surface and in cells distributed adjacent to the ventricles 
(Schmid et al. 2006). These results are in good agreement 
with our own observations. As shown in Figure 2, 
FABP7-expressing cells with a process towards the 
surface of the brain can be found in the subpial 
compartment in C57BL6 mice (Fig. 2A) and also in the 
normal appearing gray matter of MS patients (Fig. 2B). In 
addition, ovoid-shaped FABP7-expressing cells are seen 
within the murine white matter (Fig. 2D) and normal 
appearing white matter of humans MS subjects (Fig. 2E).  
 Results of several studies implicate that FABP7 
is involved in pathological processes of the adult CNS. 
FABP7 expression is increased within different 
hippocampal sub-regions in response to cerebral ischemia 
in young adult monkeys (Ma et al. 2010). Transient, 
complete, whole-brain ischemia was induced in young 
adult monkeys (Macaca fuscata) by clamping the 
innominate and left subclavian arteries for 20 min. These 
authors were able to show that FABP7 is preliminary 
expressed by astrocytes and progenitors of the non-
injured hippocampal dentate gyrus and cornu ammonis 
region. Follwoing ischemia, FABP7 expression was 
increased within the hippocampus and co-localized to 
proliferating cells. White and colleagues (2010) 
investigated the expression of FABP7 in response to 
contusive spinal cord injury in mice (White et al.). In the 
control spinal cord, FABP7 expression was restricted to a 
small number of cell bodies in the gray matter, a few cell 
 
 
Fig. 1. Remyelination capacity after cuprizone-induced acute (5 weeks) and chronic (13 weeks) demyelination is shown by anti-PLP and 
anti-APC (inserts) staining, respectively. In control animals, the corpus callosum (CC) (arrow), cortex (star) and basal ganglia complex
(arrowhead) are well-myelinated (a). (b) and (c) show that the CC and other brain regions are severely demyelinated after 5 (b) and 
13 (c) weeks cuprizone treatment. Note that significant remyelination occurs after acute demyelination, indicated by the recovery of PLP
immunoreactivity mainly within the lateral part of the CC (arrow in d) and the laterally orientated basal ganglia complex (arrowhead in 
d), whereas these regions are devoid of any PLP+ fibers in the chronically demyelinated group (e). Both lesions contain APC+
oligodendrocytes (inserts in d/e). Scale bars: 1 mm (a-e) 
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bodies in the superficial dorsal horn, and cells contacting 
the pia mater in the periphery of the white matter. This 
study was the first to characterize the distribution of 
FABP7 immunoreactivity over time in the injured rodent 
spinal cord. In the lesion border and spared white matter 
(i.e. lesion border), FABP7 expression was strongly up-
regulated and co-localized with GFAP expression. 
Furthermore, transient induction of FABP7 expression 
occurred in cells lining the central canal and in a unique 
population of small cells found within the lesion and in 
gray matter rostral and caudal to the lesion border. A 
subset of these cells was labelled with BrdU. Seven days 
after the injury, this cell type was no longer seen. 
Additional experiments revealed that some of these cells 
were positive for nestin 24 h after the injury. The authors 
proposed that these cells represent precursors committed 
to differentiate into mature astrocytes.  
 After acute cuprizone-induced demyelination, 
we observed two distinct populations of FABP7-
expressing cells. As shown in Figures 2g-i, one 
population resembled multi-process-bearing astrocytes 
(arrow), whereas another population were round shaped 
without cell processes (arrowhead). Immunofluorescence 
double-labelling revealed that FABP7-expressing cells 
with an astrocytes-like morphology are GFAP-positive. 
In contrast, round shaped FABP7+ cells do not co-stain 
with GFAP. Thus, the presence of FABP7+/GAFP+ and 
FABP7+/GAFP– cell populations are not restricted to 
contusive spinal cord injury but can also be found in the 
toxic demyelination model.  
 FABP7 expression is induced in astrocytes and 
Müller glial cells in rats subjected to kainate acid 
 
 
Fig. 2. Morphology of FABP7-expressing cells in the murine and human brain. (a) shows FABP7-expressing cells in the subpial 
compartment of control animals. (b) shows FABP7-expressing cells in the same compartment of the human brain surrounded by normal
appearing gray matter (c). (d) shows round-shaped FABP7-expressing cells in the CC of control animals. (e) shows FABP7-expressing 
cells in the normal appearing human white matter with the respective anti-PLP staining (f). Inserts (d/e) show the same cells at higher 
magnification. (g) shows stellate-shaped (higher magnification in h) and round-shaped (higher magnification in i) FABP7-expressing 
cells after cuprizone-induced demyelination (5 weeks, 0.2 %). Scale bars: 160 µm 
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treatment which leads to neuronal degeneration in the 
retina (Chang et al. 2007). Thus, astrocytes appear to de-
differentiate after kainate acid-induced retinal 
degeneration. Bannerman and colleagues recently 
demonstrated that FABP7/GFAP double-positive cells 
accumulate within the spinal cord in MOG-induced EAE 
in mice (Bannerman et al. 2007). Twenty one days after 
immunization with MOG, FABP7-expressing cells with a 
multiprocess-bearing morphology appeared within and at 
the margin of the inflamed lesions. These studies clearly 
show that (i) FABP7 expression is dynamically regulated 
during various types of brain injury and (ii) is induced in 
activated GFAP+ astrocytes as well as in not further 
characterized GFAP– cells.  
 
Role of FABP7 expression in astrocytes 
 
 The putative function of FABP7 in the brain 
comes from studies of anaplastic astrocytomas (grade III 
astrocytoma) and glioblastoma multiforme (GBM; grade 
IV astrocytoma), collectively called malignant gliomas 
(MG) which are the most common cancer types in the 
CNS (Mita et al. 2007). FABP7 is found in astrocytoma 
tumor biopsies and in a subset of MG cell lines. 
Expression levels of FABP7 are increased in brain tumor 
tissue compared to the normal adult brain (Godbout et al. 
1998, Sanai et al. 2005). Most importantly, FABP7 levels 
are associated with decreased survival times and/or tumor 
progression in patients with grade IV astrocytoma (Feng 
et al. 1994, Sanai et al. 2005). Notably, nuclear FABP7 
staining had a clear negative correlation with survival of 
GBM patients (Liang et al. 2005). FABP7 appears to 
regulate cell morphology in MG cell lines (Mita et al. 
2007). In vitro FABP7-negative U87 MG cells had a 
stellate appearance with short processes. Stable 
transfection of those cells with a human FABP7 
expression construct induced the formation of extended 
bipolar processes often spanning considerable distances 
(up to 250 μm). These elongated processes were similar 
in appearance to radial glial processes that can span the 
entire width of the cortical wall during brain 
development. Concordantly, depletion of FABP7 in 
FABP7-expressing MG cell lines resulted in a loss of 
elongated processes which was associated with a reduced 
cell migration and invasion. On the subcellular level, 
FABP7 co-localizes with F-actin in U251 cells (Mita et 
al. 2007).  
 How might these findings be interpreted in the 
context of astrocyte-regulated remyelination? It is 
obvious that pro-myelinating factors such as IGF-1,  
FGF-2, and PDGF-A can interact with their target cells 
most efficiently if they are released in close vicinity to 
OPC. As an example, IGF binding protein regulates IGF-
1 protein tissue distribution and inhibits the binding of 
IGF-1 to its cognate receptor (Kooijman et al. 2009). 
Thus, increased astrocyte migration might stimulate 
remyelination by increasing local levels of IGF-1 in the 
peri-cellular space of OPC.  
 Function of FABP7-expressing astrocytes also 
depends on the presence or absence of FABP7 ligands 
such as fatty acids. In vitro ligand binding studies have 
shown that the polyunsaturated fatty acid (PUFA), ω-3 
docosahexaenoic acid (DHA; 22:6) is the preferred ligand 
of FABP7. FABP7 also binds ω-6 arachidonic acid (AA; 
20:4), albeit with a ~4-fold lower affinity (Balendiran et 
al. 2000). Highly unsaturated long-chain fatty acids alter 
the structure and function of membranes, increasing their 
fluidity, elasticity, and permeability, and potentially 
affecting signal transduction and gene expression 
(Hashimoto et al. 1999, Rojas et al. 2003, Stillwell and 
Wassall 2003). Preferential localization of FABP7 at the 
leading edges of astrocytes may result in increased PUFA 
content at these sites. Increased fluidity may directly 
influence cell motility or may activate cell signalling 
events associated with cell motility und thus further 
diminish the gap between OPC and astrocytes processes. 
Mita et al. (2010) showed that FABP7-induced MG cell 
migration is fatty acid ligand-dependent since growth of 
FABP7-expressing U87 cells in DHA resulted in a 5-fold 
decrease in cell migration studies. In contrast, FABP+ 
U87 cells cultured in AA showed a small but significant 
increase in cell migration. These results indicate a strong 
link between FABP7-mediated cell migration and 
presence of DHA or AA. To address whether the ratio of 
DHA:AA, as opposed to individual concentrations of 
DHA or AA, is driving the effects on cell migration, 
U87-FABP7+ MG cells were treated with varying 
concentrations of DHA and AA, and their migration 
performance was measured. The ratio of DHA:AA 
determined the migration of FABP7-expressing U87 MG 
cells. When levels of AA exceeded those of DHA by 3-
fold or more, the inhibitory effects of DHA on cell 
migration were negated. These results are expected in 
light of in vitro data indicating that DHA has a 4-times 
greater binding affinity for FABP7 than AA (Balendiran 
et al. 2000). Moreover, these studies provide evidence 
that FABP7 localization to the nucleus is not required for 
FABP7-mediated cell migration; however, inhibition of 
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migration by DHA is dependent on localization of 
FABP7 to the nucleus.  
 The cause of MS is unknown. The geographic 
distribution and epidemiological risk factors such as 
emigration suggest the importance of environmental 
factors (Ascherio and Munger 2007). Differences in the 
diet composition have been suggested as one explanation 
for the geographic distribution of MS. In a recent work, 
Bo et al. (2009) investigated the effects of dietary 
intervention on MRI activity and de- and remyelination in 
the cuprizone model (Torkildsen et al. 2009a, Torkildsen 
et al. 2009b). An interesting outcome of their studies was 
that mice fed on a diet with soybean-oil cuprizone (high 
ω-6/ω-3 ratio) tended to a more extensive remyelination 
than mice fed cod liver-oil cuprizone (low ω-6/ω-3 ratio). 
It would be interesting to determine whether the levels of 
individual PUFAs such as DHA and AA (or their 
respective ratio) differ in remyelinating veruses non-
remyelinating MS lesions and, thus, might contribute to 
remyelination failure during chronic MS courses. 
 
Conclusion 
 
 Demyelination is still regarded as a pathological 
hallmark of MS but it has become increasingly apparent 
in recent years that substantial axonal and neuronal loss 
are equally important features (Baracskay et al. 2002, 
Geurts and Barkhof 2008, Geurts et al. 2009). 
Remyelination is the best-documented and most robust 
example of tissue repair in the human CNS and is 
unequivocally neuroprotective in MS. Approximately 
40 % of post-mortem MS tissues demonstrate 
remyelination which can occur early and late during the 
course of MS (Patrikios et al. 2006, Franklin and 
Ffrench-Constant 2008, Irvine and Blakemore 2008). 
Remyelination is believed to restore the structural 
integrity of the axon-myelin unit and axonal conduction 
properties that are lost following demyelination (Smith et 
al. 1979, Halliday 1981). It is unresolved why in some 
patients remyelination is widespread while it is sparse in 
other patients. The importance of axonal damage and loss 
as the pathological basis for progressive loss of function 
in MS demands a better understanding of remyelination 
processes and possible reasons for its failure. Several 
mechanisms have been suggested that may result in a 
blockade of remyelination. The loss and destruction of 
OPC within the lesions in the course of repeated de- and 
remyelination (Prineas et al. 1993a, Prineas et al. 1993b) 
might play a role. In some lesions, however, progenitor 
cells are abundantly present (Scolding et al. 1998, 
Wolswijk 1998, Chang et al. 2000, Chang et al. 2002) but 
remyelination still fails either because axons are not 
permissive for remyelination (Charles et al. 2002) or the 
maturation of progenitor cells is inhibited (John et al. 
2002). Taken together, results from our group and others 
strongly implicate that astrocytes actively participate in 
the course of MS disease. Impaired FABP7 signalling 
might be a major characteristic for the failure of 
remyelination and progression of clinical disability. 
Further studies have to verify our hypothesis. 
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